Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe COVID-19

Next Previous
Trial Profile

A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe COVID-19

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remdesivir (Primary)
  • Indications COVID 2019 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms SIMPLE; SIMPLE-severe
  • Sponsors Gilead Sciences

    • Most Recent Events

    • 24 Jun 2021 Results of an analysis assessing all cause mortality hazard ratios, overall and stratified by baseline oxygen ; data were used from this trial and compared with a study GS-US-540-5807 (EUPAS34303; a real-world retrospective longitudinal cohort study) presented at the World Microbe Forum 2021
    • 10 Mar 2021 Results assessing final comparative analysis from two studies: a prospective phase 3, randomized study of RDV (n=368; RDV cohort- final Day 28 (D28) analysis of NCT04292899) vs standard of care (SOC) (n= 1399; interim Day 14 [D14] analysis of a real-world retrospective cohort study of SOC (non-RDV cohort), presented at the 28th Conference on Retroviruses and Opportunistic Infections
    • 25 Oct 2020 Results (n=397) assessing regional differences in clinical outcomes of severe COVID-19 patients treated with RDV, presented at the IDWeek 2020
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top